Induced association of μ opioid (MOP) and type 2 cholecystokinin (CCK 2) receptors by novel bivalent ligands

Journal of Medicinal Chemistry

Volumn 52, Issue 2, 2009, Pages 247-258

  Zheng, Yaguo ^a   Akgiin, Eyup ^a   Harikumar, Kaleeckal G ^b   Hopson, Jessika ^b   Powers, Michael D ^a   Lunzer, Mary M ^a   Miller, Laurence J ^b   Portoghese, Philip S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; AMINO 1,3 DIHYDRO 1 METHYL 5 PHENYL 2H 1,4 BENZODIAZEPIN 2 ONE; BENZODIAZEPIN 2 ONE DERIVATIVE; CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; G PROTEIN COUPLED RECEPTOR; HETERODIMER; IODINE 125; LIGAND; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; N METHYL 2 [13 [3 [3 (1 METHYL 2 OXO 5 PHENYL 2,3 DIHYDRO 1H BENZO[E][1,4]DIAZEPIN 3 YL)UREIDO]PHENOXY] 2,6,10 TRIOXO 8 OXA 3,5,11 TRIAZATRIDECYLOXY]ACETAMIDE; OXYMORPHONE; TRITIUM; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CALCIUM MOBILIZATION; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN COS1; CENTRAL NERVOUS SYSTEM; CHO CELL; CHRONIC PAIN; CONTROLLED STUDY; DIMERIZATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; MALE; MASS SPECTROMETER; MOLECULAR INTERACTION; MORPHINE TOLERANCE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PAIN; PHARMACOPHORE; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR BLOCKING; TAIL FLICK TEST; ANIMAL; CERCOPITHECUS; CRICETULUS; ENERGY TRANSFER; HAMSTER; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BINDING;

ANIMALS; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CRICETULUS; DIMERIZATION; ENERGY TRANSFER; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; PROTEIN BINDING; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, OPIOID, MU;

EID: 60549111230     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800174p     Document Type: Article

References (64)

1. IUPHAR receptor database, opioid receptors. http://uphar-db.org/PRODGPCR.
2. Gutstein, H. B.; Akil, H. Opioid Analgesics. In Goodman and Gillman's the Pharmacological Basis of Therapeutics, 11th ed.; McGraw-Hill: New York, 2006, Chapter 21.
3. Saito, A.; Goldfine, I. D.; Williams, J. A. Characterization of receptors for cholecystokinin and related peptides in mouse cerebral cortex. J. Neurochem. 1981, 37, 483-490.
4. Wank, A.; Harkins, R.; Jensen, R. T.; Shapira, H.; DeWeerth, A.; Slatery, T. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from ret pancreas. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3125-3129.
5. Kopin, A. S.; Lee, Y-M.; McBride, E. W.; Miller, L. J.; Lu, M.; Lin, H. Y.; Kolakowski, L.F., Jr.; Beinborn, M. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3605-3609.
6. Ulrich, C. D.; Ferber, I.; Holicky, E.; Buell, G.; Miller, L. J. Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. Biochem. Biophy. Res. Commun. 1993, 193, 204-211.
7. Pisegna, J. R.; De Weerrth, A.; Huppi, K.; Wank, S. A. Molecular cloning of the human brain and gastric cholocystokinin receptor: structure, functional expression and chromosal localization. Biochem. Biophys. Res. Commun. 1992, 189, 296-303.
8. Holicky, E. L.; Hadac, E. M.; Ding, X.-Q.; Miller, L. J. Molecular characterization and organ distribution of type A and B cholocystokinin receptors in cynomolgus monkey. Am. J. Physiol.: Gastrointest. Licer Physiol. 2001, 281, G507-G514.
9. Noble, F.; Roques, B. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Pros. Neurobiol. 1999, 58, 349-379.
10. Saito, A.; Sankaran, H.; Goldfine, I. D.; Williams, J. A. Cholecytokinin receptors in the brain: characterization and distribution. Science 1980, 208, 1155-1156.
11. Steengard-Pedersen, K.; Larson, L.-I. Localization and opiate receptor binding of enkephalin, CCK and ACTH/β-endorphin in the rat central nervous system. Peptides 1981, 2, 3-19.
12. Gall, C.; Lauterborn, J.; Burks, D.; Scroogy, K. Co-localization of enkephalin and chlolecystokinin in discrete areas of rat brain. Brain Res. 1987, 403, 403-408.
13. 2 receptor gene reduces mechanical sensitivity and abolishes the development of hyperalgesia in monon- europathic mice. Eur. J. Neurosci. 2004, 20, 1577-1586.
14. Pommier, B.; Beslot, F.; Simon, A.; Pophillat, M.; Matsui, T.; Dauge, V.; Roques, B. P.; Noble, F. Deletion of CCK2 receptor in mice results in an up regulation of the endogenous opioid system. J. Neurosci. 2002, 22, 2005-2011.
15. Friedrich, A. E.; Gebhart, G. F. Modulation of visceral hyperalgesia by morphine and cholecystokinin from the rat rostroventral medial medulla. Pain 2003, 104, 93-101.
16. Xie, J. Y.; Herman, D. S.; Stiller, C.-O.; Gardell, L. R.; Ossipov, M. H.; Lai, J.; Porreca, F.; Vanderah, T. W. Cholecystokinin in the rostral venromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J. Neurosci. 2005, 25, 409-416.
17. Kalso, E. Improving opioid effectiveness: from ideas to evidence. Eur. J. Pain 2005, 9, 131-135.
18. George, S. R.; Fan, T.; Xie, Z.; Tse, R.; Tam, V; Varghese, G.; O'Dowd, B. F. Oligomerization of μ- and δ-opioid receptors. J. Biol. Chem. 2000, 275, 26128-26135.
19. Gomes, I.; Jordan, B. A.; Gupta, A.; Trapaidze, N.; Nagy, V.; Devi, L. A. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J. Neurosci. 2000, 20, RC110.
20. Wang, D.; Sun, X.; Bohn, I. M.; Sadee, W. Opioid receptor homo-and heterodimerization in living cells by quantative bioluminescence resonance energy transfer. Mol. Pharmacol. 2005, 67, 21713-2184.
21. Erez, M.; Takemori, A. E.; Portoghese, P. S. Narcotic antagonist potency of bivalent ligands which contain β-naltrexamine. Evidence for bridging between proximal recognition sites. J. Med. Chem. 1982. 25, 847-849.
22. Portoghese, P. S.; Larson, D. L.; Yim, C. B.; Sayre, L. M.; Ronsisvalle, G.; Lipkowski, A. W.; Takemori, A. E.; Rice, K. C.; Tam, S. W. Stereostructure-activity relationship of opioid agonist and antagonists ligands. Evidence for bridging between vicinal opioid receptors. J. Med. Chem. 1985, 28, 1140-1141.
23. 2 phenotypes. Selective targeting of delta-kappa heterodimers. J. Med. Chem. 2004, 47, 2969-2972.
24. 1 opioid receptor phenotypes. J. Med. Chem. 2005, 48, 1713-1716.
25. (a) Portoghese, P. S.; Larson, D. L.; Sayre, L. M.; Yim, C. B.; Ronsisvalle, G.; Tam, S. W.; Takemori, A. E. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. J. Med. Chem. 1986, 29, 1855-1861.
26. (b) Daniels, D. J.; Lenard, N. R.; Roerig, S. C.; Portoghese, P. S. Tolerance and Dependence Is Modulated by the Distance between Opioid mu Agonist and delta Antagonist Pharmacophores in a Bivalent Ligand Series (MDAN). Evidence for Associated mu and delta Opioid Pharmacophores. Presented at the 2004 INRC, Kyoto, Japan, July 18-22, 2004.
27. (c) Portoghese, P. S.; Ronsisvalle, G.; Larson, D. L.; Yim, C. B.; Sayre, L. M.; Takemori, A. E. Opioid agonist and antagonist bivalent ligands as receptors probes. Life Sci. 1982, 31, 1283-1286.
28. (d) Xie, Z.; Bhushan, R. G.; Daniels, D. J.; Portoghese, P. S. Interaction of biavalent ligand KDN21 with heterodimeric δ-κ opioid receptors in human embryonic kidney 293 cells. Mol. Pharmacol. 2005, 68, 1079-1086.
29. Sayre, L. M.; Portoghese, P. S. Stereospecific synthesis of 6α-and 6β-amino derivatives of naltrexone and oxymorphone. J. Org. Chem. 1980, 45, 3366-3368.
30. Bock, M. G.; DiPardo, R. M.; Evans, B. E.; Rittle, K. E.; Whitter, W. L.; Garsky, V. M.; Gilbert, K. F.; Leighton, J. L.; Carson, K. L.; Mellin, E. C.; Veber, D. F.; Chang, R. S. L.; Lotti, V. J.; Freedman, S. B.; Smith, A. J.; Patel, S.; Anderson, P. S.; Freidinger, R. M. Development of 1,4-benzodiazepine cholecystokinin type B antagonists. J. Med. Chem. 1993, 36, 4276-4292.
31. Watkins, L. R.; Kinscheck, I. B.; Mayer, D. J. Potentiation of opiate analgesia and apperant reversal of morphine tolerance by proglumide. Science 1984, 224, 395-396.
32. Lu, L.; Huang, M.; Liu, A.; Ma, L. Cholecystoinen-B receptor antagonists attenuate morphine dependence and withdrawal in rats. NeuroReport 2000, 11, 829-832.
33. Daniels, D. J.; Lenard, N. R.; Etienne, C. L.; Law, P.-Y.; Roerig, S. C.; Portoghese, P. S. Opioid-induced tolerance and dependence in mice modulated by the bivalent ligand series. Proc. Natl. Acad. Sc.i U.S.A. 2005, 102, 19208-19213.
34. Bock, M. G.; Dipardo, R. M.; Evans, B. E.; Rittle, K. E.; Veber, D. F.; Freidinger, R. M.; Hirshfield, J.; Sringer, J. P. Synthesis and resolution of 3-amine-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones. J. Org. Chem. 1987, 52, 3232-3239.
35. Reider, P. J.; Davis, P.; Hughes, D. L.; Grabowski, E. J. J. Crystallization-induced asymmetric transformation: stereospecific synthesis of a potent peripheral CCK antagonist. J. Org. Chem. 1987, 52, 955-957.
36. Wubbels, G. G.; Halverson, A. M.; Oxman, J. D.; Bruyn., V. H. Regioselectivity of photochemical and thermal smiles rearrangements and related reaction of β-(nitrophenoxy)ethylamines. J. Org. Chem. 1985, 50, 4499-4504.
37. Cheng, Z. J.; Harikumar, K. G.; Holicky, E. L.; Miller, L. J. Heterodimerization of Type A and B Cholecystokinin Receptors Enhance Signaling and Promote Cell Growth J. Biol. Chem. 2003, 278, 52972-52979.
38. Gomes, I.; Filipovska, J.; Jordan, B. A.; Devi, L. A. Oligomerization of opioid receptors. Methods 2002, 27, 358-365.
39. Waldhoer, M.; Fong, J.; Jones, R. M.; Lunzer, M. M.; Sharma, S. K.; Kostenis, E.; Portoghese, P. S.; Whistler, J. L. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimmers. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 9050-9055.
40. Rozenfeld, R.; Devi, L. A. Receptor heterodimerization leads to a switch in signaling: β-arrestin2-mediated ERK activation by μ-δ opioid receptor heterodimer. FASEB J. 2007, 21, 2455-2465.
41. Gupta, A.; Décaillot, F. M.; Devi, L. A. Targeting opioid receptor heterodimers: strategies for screening and drug development. AAPS J. 2006, 8, E153-E159.
42. Milligan, G. G protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. Drug Discovery Today 2006, 11, 541-549.
43. Rashid, A. J.; O'Dowd, B. F.; George, S. R. Minireview: diversity and complexity of signaling through peptidergic G protein-coupled receptors. Endocrinology 2004, 145, 2645-2652.
44. (a) Lee, P. S.; O'Dowd, B. F.; George, S. R. Homo- and hetero-oligomerization of G protein-coupled receptors. Life Sci. 2003, 74, 173-180.
45. (b) Pan, Y.-X.; Bolan, E.; Pasternak, G. W. Dimerization of morphine and orphinan FQ/nociception receptors: generaton of novel receptor subtype. Biochem. Biophys. Res. Commun. 2002, 297, 659-663.
46. (c) Wang, H. L.; Hsu, C. Y.; Huang, P. C.; Kuo, Y. L.; Li, A. H.; Yeh, T. H.; Tso, A. S.; Chen, Y. L. Heterodimerization of opioid receptor-like1 and mu opioid receptors impairs the potency of mu receptor agonist. J. Neurochem. 2005, 92, 1285-1294.
47. (d) Jordan, B. A.; Trapaidza, N.; Gomes, I.; Nivarthi, R.; Devi, L. A. Oligomerization of opioid receptors with beta-2 adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 343-348.
48. (e) Pfeiffer, M.; Koch, T.; Schroeder, H.; Laugusch, M.; Hollt, V.; Schulz, S. Heterodimerization of somastatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J. Biol. Chem. 2002, 277, 19762-19772.
49. (f) Chen, C.; Li, J.; Bot, G.; Szabo, I.; Rogers, T. J.; Liu- Chen, L.-Y. Heterodimerization and cross-desenitization between the μ-opioid receptor and the chemokine CCR5 receptor. Eur. J. Pharmacol. 2004, 483, 175-186.
50. (g) Suzuki, S.; Chuang, L. F.; Yau, P.; Doi, R. H.; Chuang, R. Y. Interaction of opioid and chemokine receptors: oligomerization of mu, kappa, and delta with CCR5 on immune cells. Exp. Cell Res. 2002, 280, 192-200.
51. (h) Pfeiffer, M.; Kirsch, S.; Stumm, R.; Koch, T.; Wu, D.; Laugusch, M.; Schroeder, H.; Hollt, V.; Schulz, S. Heterodimerization of substance P and μ-opioid receptors regulates receptor trafficking and resensitization. J. Biol. Chem. 2003, 51, 51630-51637.
52. (i) Jordan, B. A.; Gomes, I.; Rios, C.; Filipovska, J.; Devi, L. A. Functional interactions between mu opioid and alpha2A-adrenergic receptors. Mol. Pharmacol. 2003, 64, 1317-1324.
53. (j) Zhang, Y. D.; Limbird, L. E. Hetero-oligomers of alpha2A-adrenergic receptor and mu-opioid receptor do not lead to transactivation of G protein or altered endocytosis profiles. Biochem. Soc. Trans. 2004, 32, 856-860.
54. (k) Rios, C.; Gomes, I.; Devi, L. A. Interaction between delta opioid receptors and alpha2A-adrenoceptors. Clin. Exp. Pharmacol. Physiol. 2004, 31, 833-836.
55. (l) Rios, C.; Gomes, I.; Devi, L. A. Mu and CB1 cannabinoid receptor interaction: reciprocal inhibition of receptor signaling and neuritogenesis. Br. J. Pharmacol. 2006, 148, 387-395.
56. (m) Parenty, G.; Appelbe, S.; Milligan, G. CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of CXCR2-DOP receptor heterodimer. Biochem. J. 2008, 412, 245-256.
57. Harikumar, K. G.; Morfis, M. M.; Lisenbee, C. S.; Sexton, P. M.; Miller, L. J. Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors. Mol. Pharmacol. 2006, 69, 363-373.
58. Hadac, E. M.; Ghanekar, D. V.; Holicky, E. L.; Pinon, D. I.; Dougherty, R. W.; Miller, L. J. Relationship between native and recombinant cholecystokinin receptors: role of differential glycosylation. Pancreas 1996, 13, 130-139.
59. Harikumar, K. G.; Dong, M.; Cheng, Z.; Pinon, D. I.; Lybrand, T. P.; Miller, L. J. Transmembrane segment peptides can disrupt cholecys-tokinin receptor oligomerization without effecting receptor function. Biochemistry 2006, 45, 14706-14716.
60. Munson, P. J.; Rodbard, D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 1980, 107, 220-239.
61. D'Amour, F. E.; Smith, D. L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 1941, 72, 74-79.
62. Dewey, W. L; Harris, L. S; Howes, J. F.; Nuite, J. A. The effect of various neurochemical modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests. J. Pharmacol. Exp. Ther. 1970, 175, 435-442.
63. Harris, L. S.; Pierson, A. K. Some narcotic antagonists in the benzomorphan series. J. Pharmacol. Exp. Ther. 1964, 143, 141-148.
64. Haley, T. J; McCormick, W. G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br. J. Pharmacol. Chemother. 1957, 12, 12-15.